Product Information
CAPLYTA 10.5 MG CAPSULE is a brand product labeled by Intra-Cellular Therapies, Inc, priced at $57.2430 per EA under NDC 72060011040. Its NADAC has been published 189 times since Feb 22, 2023.
FDA first approved this application on Dec 20, 2019.
Strength
10.5 mg/1
Manufacturer
Intra-Cellular Therapies, IncNDC
72060011040
Classification
Brand
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LUMATEPERONEApproval Type
New Drug (NDA)
FDA Application
NDA209500FDA Approved
12/20/2019
On Market Since
8/9/2022
Pharmacological Classes
Price Statistics
The NADAC for CAPLYTA 10.5 MG CAPSULE has been published 189 times since Feb 22, 2023, and over the history we have for it it has risen 14.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $57.2430 per EA |
|---|---|
| All-time high | $57.3988 (May 13, 2026) |
| All-time low | $50.0661 (Feb 22, 2023) |
| 52-week high | $57.3988 |
| 52-week low | $54.6431 |
| Median price | $53.2566 |
| Average price | $53.6829 |
| Largest weekly change | +5.9% (Jan 3, 2024) |
| Weeks tracked | 189 |
| Tracking since | Feb 22, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the lumateperone market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Intra-Cellular Therapies, Inc manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
lumateperone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CAPLYTA 10.5 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for CAPLYTA 10.5 MG CAPSULE, manufactured by Intra-Cellular Therapies, Inc, is $57.2430 per EA (NDC 72060011040), effective Sep 30, 2026.
How has the price of CAPLYTA 10.5 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for CAPLYTA 10.5 MG CAPSULE has risen 14.3%. It has been tracked across 189 weekly CMS publications since Feb 22, 2023.
What are the highest and lowest recorded NADAC prices for CAPLYTA 10.5 MG CAPSULE?
Since Feb 22, 2023, the NADAC for CAPLYTA 10.5 MG CAPSULE has ranged from a low of $50.0661 (Feb 22, 2023) to a high of $57.3988 (May 13, 2026), with a median of $53.2566 per EA.
Are there cheaper alternatives to CAPLYTA 10.5 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of CAPLYTA 10.5 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CAPLYTA 10.5 MG CAPSULE?
CAPLYTA 10.5 MG CAPSULE (NDC 72060011040) is labeled by Intra-Cellular Therapies, Inc, and CMS classifies it as a brand product.